New And Special Drugs
-
Qiyoukang (Gumokimab) – Plaque Psoriasis | HongKong DengYue Medicine
-
Lukeda (Rocbrutinib) – MCL | HongKong DengYue Medicine
-
Epkinly (Epcoritamab) – Follicular Lymphoma | HongKong DengYue Medicine
-
Blenrep (Belantamab Mafodotin) – Multiple Myeloma | HongKong DengYue Medicine
-
Hyrnuo (Sevabertinib) – NSCLC | HongKong DengYue Medicine
-
Foundayo(Orforglipron) – Obesity/Overweight | HongKong DengYue Medicine
-
Exdensur (Depemokimab) – Eosinophilic Asthma | HongKong DengYue Medicine
-
Zometa (Zoledronic Acid) – HCM | HongKong DengYue Medicine
What Can We Offer You?
Generic drugs
Dedicated to providing high-quality, affordable medicines around the world
Vitamins and Supplements
A balanced diet by addressing different deficiencies with the right dosage
brand name medicines
DengYue Medicine as China Drug Import and Export Wholesaler, fills the gap between quality and quantity by adding some affordability
Fast-moving consumer goods
Stock a full range of products from sanitary napkins to foot care creams for your daily needs
non-prescription drugs
Flagship OTC brand - approved and accepted by global standards
Medical supplies and auxiliary supplies
Explore continually updated supplies, diagnostic equipment and essential tools
News
HongKong DengYue Medicine Wholesaler focus on medical trends and obtain new drug directions.
Gumokimab Approved for Plaque Psoriasis in China: The IL-17A Therapy Landscape Continues to Evolve
On June 11, Akeso announced that its self-developed IL-17A monoclonal antibody, Gumokimab (AK111, brand name Qiyoukang®), received approval from China’s National Medical Products Administration (NMPA)
10 Common Questions Cancer Patients Ask: From Survival Rates to Treatment Options
Cancer treatment is often a long and uncertain journey. Global pharmaceutical distributor DengYueMed has organized the 10 common questions cancer patients ask to help patients
Mazdutide vs Semaglutide: ADA 2026 DREAMS-3 Trial Shows Superior Efficacy in Type 2 Diabetes With Obesity
On June 8, Innovent Biologics announced the results of the Phase III DREAMS-3 head-to-head trial of Mazdutide vs Semaglutide at the 2026 American Diabetes Association
New Hemophilia Drug Approved in China: Bemiltenase Alfa Becomes World’s First Factor X Activator
On June 4, 2026, the NMPA officially announced that injectable Bemiltenase alfa (STSP-0601), a Class 1 innovative biologic developed by BioJeTay, a subsidiary of Shutaishen
Access Pathways for Innovative Medicines in China: Hospitals, Pharmacies, and Pharmaceutical Distribution Channels
More and more overseas patients are beginning to explore China’s innovative drug resources in search of new treatment opportunities. However, for international patients, the real
May 2026 China Innovative Drug Approvals: 5 Major New Drugs Approved
China’s innovative drug industry continues to achieve major breakthroughs. According to public information released by China’s National Medical Products Administration (NMPA), May 2026 China innovative
Which Cancers Does China Have Advantages In? Top 5 Areas of Strength Explained
From precision medicine to immunotherapy, from novel targeted drugs to cell therapy, China has formed unique strengths in several cancer treatment fields. As a platform
Causes of the Global Counterfeit Drug Problem and Safe Pharmaceutical Procurement Guide
In today’s increasingly complex pharmaceutical distribution system and highly active cross-border trade environment, counterfeit medicines have evolved from a national regulatory issue into a global
Fast And Safe Delivery
Global Transportation Express
Temperature-controlled Transport
Safe Transportation, GDP Compliant
